Bros. Advisors Lp Baker Purchases 310,559 Shares of KALA BIO, Inc. (NASDAQ:KALA) Stock

KALA BIO, Inc. (NASDAQ:KALA) major shareholder Bros. Advisors Lp Baker acquired 310,559 shares of KALA BIO stock in a transaction dated Monday, December 30th. The stock was bought at an average price of $6.44 per share, for a total transaction of $1,999,999.96. Following the completion of the transaction, the insider now directly owns 1,083,398 shares of the company’s stock, valued at approximately $6,977,083.12. This represents a 40.18 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

KALA BIO Stock Performance

KALA BIO stock opened at $6.94 on Thursday. The firm has a market capitalization of $31.99 million, a P/E ratio of -0.56 and a beta of -2.15. The stock has a fifty day moving average price of $6.64 and a 200 day moving average price of $6.25. KALA BIO, Inc. has a 52 week low of $4.21 and a 52 week high of $9.25. The company has a current ratio of 2.15, a quick ratio of 2.15 and a debt-to-equity ratio of 3.18.

KALA BIO (NASDAQ:KALA) last released its earnings results on Tuesday, November 12th. The company reported ($1.93) EPS for the quarter, beating the consensus estimate of ($2.43) by $0.50. Equities research analysts anticipate that KALA BIO, Inc. will post -10.84 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and issued a $15.00 price objective on shares of KALA BIO in a research report on Friday, November 15th.

Hedge Funds Weigh In On KALA BIO

An institutional investor recently bought a new position in KALA BIO stock. SR One Capital Management LP purchased a new position in shares of KALA BIO, Inc. (NASDAQ:KALA) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 443,661 shares of the company’s stock, valued at approximately $3,146,000. KALA BIO comprises about 1.0% of SR One Capital Management LP’s portfolio, making the stock its 9th biggest position. SR One Capital Management LP owned about 15.76% of KALA BIO at the end of the most recent quarter. Institutional investors own 24.61% of the company’s stock.

KALA BIO Company Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.